Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

This phase 3a trial evaluated the efficacy and safety of coadministered cagrilintide and semaglutide (CagriSema) in adults with overweight or obesity. Participants (N=3417) were randomized to receive CagriSema (2.4 mg each), semaglutide alone, cagrilintide alone, or placebo for 68 weeks. CagriSema resulted in a mean weight loss of 20.4% (vs. 3.0% with placebo; P<0.001), with 91.9% achieving ≥5% weight loss and 53.6% achieving ≥20% weight loss. The combination therapy also improved cardiometabolic risk factors, including systolic blood pressure and lipid levels. Gastrointestinal adverse events were common (79.6%) but mostly mild-to-moderate. CagriSema demonstrated superior weight loss compared to monotherapies, supporting its potential as an effective treatment for obesity.

This phase 3a trial evaluated the efficacy and safety of coadministered cagrilintide and semaglutide (CagriSema) in adults with overweight or obesity. Participants (N=3417) were randomized to receive CagriSema (2.4 mg each), semaglutide alone, cagrilintide alone, or placebo for 68 weeks. CagriSema resulted in a mean weight loss of 20.4% (vs. 3.0% with placebo; P<0.001), with 91.9% achieving ≥5% weight loss and 53.6% achieving ≥20% weight loss. The combination therapy also improved cardiometabolic risk factors, including systolic blood pressure and lipid levels. Gastrointestinal adverse events were common (79.6%) but mostly mild-to-moderate. CagriSema demonstrated superior weight loss compared to monotherapies, supporting its potential as an effective treatment for obesity.